कंपनी का अवलोकन
Revolution Medicines, Inc. is a clinical-stage precision oncology entity dedicated to the development of novel targeted therapies specifically designed for RAS-addicted cancers. The company operates within the healthcare sector and the biotechnology industry, focusing on advanced research and development pipelines that utilize RAS(ON) inhibitors intended for monotherapy or combination treatment with other RAS(ON) inhibitors. This biotechnology firm employs a workforce of 883 individuals to advance its mission of creating precision medicine solutions for complex oncological conditions. With a market capitalization of $19.17 billion, the company holds a significant valuation despite reporting N/A annual revenue figures in the provided data. This substantial market cap indicates that the market values the company's intellectual property and pipeline potential highly, even in the absence of traditional revenue generation or profit margins currently reflected in its financial statements.
वित्तीय स्वास्थ्य
The company reports N/A for revenue (TTM) and a net income (TTM) of $-1,131,300,992, alongside an EBITDA of $-1,174,619,008, which highlights a cost structure heavily weighted toward research, development, and operational expenses that exceed current income generation. The free cash flow stands at $-523,279,008, indicating that the company is currently burning cash rather than generating liquidity, which limits its immediate financial flexibility without external capital injections or asset monetization. Analysis of the margins reveals a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, suggesting that the company has not yet achieved profitability or that its revenue structure does not currently support positive margins at scale. On the liability side, the company holds $2.03 billion in cash against $427.15 million in debt, resulting in a debt-to-equity ratio of 26.18, which presents a complex picture of high cash reserves offset by a significant leverage ratio relative to equity. The current ratio is 7.14, which indicates a very strong short-term liquidity position capable of covering obligations many times over. However, the return on equity is -58.1% and the return on assets is -30.1%, revealing that management is currently generating negative returns on the capital invested in the business, a common characteristic in early-stage biotechnology development phases before product commercialization.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -14.36, implying that analysts or markets do not expect immediate earnings turnaround in the near term based on current projections. The price-to-book ratio is 11.68, which indicates a significant market premium over the company's book value, suggesting investors are pricing in substantial future growth potential or asset appreciation despite current operational losses. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of -14.96, which further reinforces the valuation challenge faced by companies that have not yet transitioned from a research-focused model to a profitable commercial model. The stock price has fluctuated between a 52-week high of $124.49 and a 52-week low of $29.98, showing a wide trading range that reflects the high volatility typical of clinical-stage biotechnology firms. The beta value is 1.01, indicating that the stock's price volatility is roughly in line with the broader market, suggesting that while the company is undiversified in its industry, its systematic risk is comparable to the general market index.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning there is no historical growth data available to compare earnings growth rates against revenue growth rates within the current reporting period. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, which means the company does not distribute cash to shareholders and instead retains all earnings for reinvestment into its research and development pipeline. The overall growth and income profile is characterized by a lack of current income generation and traditional growth metrics, relying entirely on the future success of its clinical pipeline and regulatory approvals to drive future expansion.